Successful treatment of Marburg virus with orally administrated T-705 (Favipiravir) in a mouse model
- 1 March 2018
- journal article
- research article
- Published by Elsevier BV in Antiviral Research
- Vol. 151, 39-49
- https://doi.org/10.1016/j.antiviral.2018.01.011
Abstract
No abstract availableKeywords
Funding Information
- Public Health Agency of Canada
- NIH (U19 AI109762-1)
- CIHR (IER-143487)
This publication has 26 references indexed in Scilit:
- Role of Human Hypoxanthine Guanine Phosphoribosyltransferase in Activation of the Antiviral Agent T-705 (Favipiravir)Molecular Pharmacology, 2013
- The Ambiguous Base-Pairing and High Substrate Efficiency of T-705 (Favipiravir) Ribofuranosyl 5′-Triphosphate towards Influenza A Virus PolymerasePLOS ONE, 2013
- Interleukin-22 Mediates Early Host Defense against Rhizomucor pusilluscan PathogensPLOS ONE, 2013
- Animal models for Ebola and Marburg virus infectionsFrontiers in Microbiology, 2013
- Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaquesProceedings of the National Academy of Sciences, 2012
- Successful Treatment of Ebola Virus–Infected Cynomolgus Macaques with Monoclonal AntibodiesScience Translational Medicine, 2012
- Clinical aspects of Marburg hemorrhagic feverFuture Virology, 2011
- Intracellular metabolism of favipiravir (T-705) in uninfected and influenza A (H5N1) virus-infected cellsJournal of Antimicrobial Chemotherapy, 2009
- Dose translation from animal to human studies revisitedThe FASEB Journal, 2007
- Mechanism of Action of T-705 against Influenza VirusAntimicrobial Agents and Chemotherapy, 2005